M. Bitzer

Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.

C. von Kalle, S. Fröhling, E. Schröck, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Bcl‐xL as prognostic marker and potential therapeutic target in cholangiocarcinoma

S. Fröhling, D. Jäger, M. Boerries, 2022, Liver international : official journal of the International Association for the Study of the Liver.

C-myc gene amplification in different stages of oesophageal squamous cell carcinoma: prognostic value in relation to treatment modality.

B. Klump, H. Gabbert, M. Sarbia, 2003, Anticancer research.

Association between NAD(P)H: Quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract

W. Schulz, D. Ross, D. Siegel, 2003, International journal of cancer.

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial.

S. Fröhling, A. Stenzinger, R. Schlenk, 2021, ESMO Open.